Prostacyclin as a cerebroprotective agent against brain hypoxia.
The cerebroprotective effect of prostacyclin (PGI2) was studied using the following methods: hypobaric hypoxia in mice, anoxic hypoxia in mice, complete ischemia by decapitation in mice, hypoventilation hypoxia in cats, and hypovolemic hypoxia in cats. PGI2 induced a dose-dependent prolongation of the survival time of mice, when administered either I.C.V. (0.001-10/micrograms/mice), I.V. (0.5-500/micrograms/kg), or I.P. (50-500/micrograms/kg). In the experiments on cats PGI2 (250 ng/kg/min I.V.) led to a significant improvement of the hypoxic ECoG. In another series of experiments, an interaction of some cerebroprotective agents with the anti-hypoxic effect of PGI2 was investigated. Piracetam, meclofenoxate, nicergoline, naftidrofuryl, cinnarizine, and nifedipine shifted the anti-hypoxic dose-response curve of PGI2 to the left indicating synergistic interaction. The results obtained suggest the function of PGI2 as a cerebroprotective prostanoid in brain hypoxia.
Nikolov
R
R
Chemical Pharmaceutical Research Institute, Sofia, Bulgaria.
D000818:Animals; D002545:Brain Ischemia / Q000503:physiopathology; D002415:Cats; D002552:Cerebral Ventricles / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology*; D011464:Epoprostenol / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D002534:Hypoxia, Brain / Q000503:physiopathology / Q000517:prevention & control*; D007276:Injections, Intraventricular; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D012769:Shock / Q000503:physiopathology / Q000517:prevention & control
D011464:Epoprostenol